drugset / Trial / NCT04398446

Effect of Hemp-CBD on Patients With CIPN

NCT04398446 ↗

Phase 2 Unknown 56 enrolled Main Line Health Ananda Hemp, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast, uterine, pancreatic, and colorectal cancer, and all stages of ovarian cancer in patients who received neoadjuvant or adjuvant therapy that included neurotoxic chemotherapeutic agents.

Timeline

Start
2020-05-27
Primary completion
2022-11-30
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified — —